Abstract CT251: Phase 3 INTerpath-009 study: Individualized neoantigen therapy V940 (mRNA-4157) plus pembrolizumab for resected stage II-IIIB (N2) NSCLC with incomplete pathological response to neoadjuvant immunochemotherapy
Authors: Tina Cascone, Nir Peled, Alona Zer, David Chism, Danko Martincic, Laureen S. Ojalvo, Joydeep Banerjee, Zheng Wang, Steven M. Keller, Jonathan D. Spicer